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1 These authors equally contributed to this work.RNA-cleaving DNAzymes were constructed to target the point mutation in the BCR–ABL transcript
that causes imatinib resistance in leukemic cells. We examined the effect of 12mer peptide nucleic
acids (PNAs) as facilitator oligonucleotides that bind to RNA substrate at the termini of the DNAzyme
to improve DNAzyme-mediated cleavage of full-length RNA. When imatinib-resistant cells were
transfected with the facilitator PNA and DNAzyme, DNAzyme activity was enhanced and the cells
were sensitized to imatinib treatment. Thus, facilitator PNA may be used to enhance activity of anti-
sense oligonucleotide targeting the full-length transcript.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Single-nucleotide polymorphisms (SNPs) caused by point muta-
tions often produce complex disease trait [1]. For example, drug
resistance in chronic myelogenous leukemia (CML) is caused by
several point mutations in the BCR–ABL fusion gene that is gener-
ated by reciprocal translocation between chromosomes 9 and 22,
t(9;22) [2,3]. Among these point mutations, The T315I mutant, in
which threonine (T) at position 315 is replaced with isoleucine
(I) because of a single base exchange (C to U) in the ABL gene, is
refractory to most tyrosine kinase inhibitors such as imatinib, nil-
otinib, and dasatinib [4,5].
Deoxyribozymes (or DNAzymes) are novel oligodeoxyribonu-
cleotides that bind and cleave speciﬁc RNA target sequences [6].
DNAzyme is an oligodeoxyribonucleotide that contains a 15-nt cat-
alytic core sequence (10–23 DNAzyme, Fig. 1A) and ﬂanking se-
quences of 7 to 8 nts for substrate binding (substrate binding
arms) [6]. DNAzyme can bind and cleave any target RNA that con-
tains a purine-pyrimidine junction. We previously designed a
method in which single-base RNA differences are detected by using
an RNA-cleaving DNAzyme (T315I DNAzyme) targeted to the T315I
point mutation in ABL RNA [7]. T315I DNAzyme was designed to
bind and cleave only the T315I mutation in ABL mRNA with achemical Societies. Published by Ematched pyrimidine base (U, boxed sequence in Fig. 1A) next to
an unpaired purine base (A). T315I DNAzyme efﬁciently cleaves
target RNA containing the T315I point mutation in vitro, in which
the RNA cleavage reaction was performed with substrate RNA of 45
nts [7].
DNAzyme may more easily ﬁnd and bind its target site in a
short RNA than in a long stretch of ABL mRNA that may contain
secondary structures. It was important to verify that the DNAzyme
can cleave its target mRNA after extraction or while it remains in
cells, wherein secondary structures may inhibit DNAzyme access
to the target sequence (Fig. 1B). Previous attempts to improve ribo-
zyme or DNAzyme activity have used facilitator oligonucleotides
that bind RNA substrate at the termini of the ribozyme or DNA-
zyme [8–12]. Alternatively, biding arm of DNAzyme has been mod-
iﬁed by incorporation of 20-O-methyl RNA or locked nucleic acid
(LNA) nucleoside analogues to enhance target afﬁnity in vitro
[13–16]. One of the facilitator oligonucleotides, peptide nucleic
acid (PNA, Fig. 1B), is a DNA/RNA mimic in which the phosphodies-
ter linkage is replaced with a peptide bond [17]. PNA provides
stronger hybridization to complementary nucleic acids by Wat-
son–Crick base pairing than do natural nucleic acids such as DNA
or RNA [17,18]. In addition, PNA binds double-stranded nucleic
acids through a strand displacement mechanism [19]. Due to
its strong hybridization capability and uncharged backbone, PNA
can invade double-stranded DNA at complementary nucleotides
[20]. These properties might be attributed to preferred use of
PNA over LNA for construction of facilitator oligonucleotides tolsevier B.V. All rights reserved.
AB
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Fig. 1. Sequences of the DNAzyme and facilitator oligoPNAs. (A) The BCR–ABL sequence near the junction between the BCR and ABL exons. The T315I point mutation (C to U)
is indicated in the ABL exon. The secondary structure of a generic ‘10–23’ DNAzyme-substrate RNA complex is shown in a box (R; purine base, Y; pyrimidine base, N; random
base). T315I DNAzyme is designed to cleave the T315I mutant RNA (sequences shown in lower case) at the point mutation (shown in boxed base). Potential sites of cleavage
by the DNAzyme are indicated by arrows. (B) The chemical structure of PNA is shown in a box. Shown is the schematic illustration of facilitator PNA function in the RNA-
cleavage reaction. The potential DNAzyme cleavage site in full-length RNA is masked by secondary structure, which makes the target site inaccessible by the DNAzyme.
Facilitator PNAs pre-form the structured substrate to expose the cleavage site (shown as a thick bar) to DNAzyme attack. (C) Sequences of the mutant ABL RNA substrate,
T315IL DNAzyme, and facilitator PNAs. PNA sequences are shown in lower case. T315IL DNAzyme is designed to anneal PNAs at the 50 and 30 termini.
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resistant to cellular nucleases and proteases, making it a promising
tool for use in cellular systems [21].
As illustrated in Fig. 1B, it may be possible to force structural
changes in substrate RNAs by using facilitator oligonucleotides
such that DNAzyme activity at long RNAs such as BCR–ABL is re-
tained or enhanced in cells. In this study, we examined binding
of facilitator PNAs at the termini of DNAzyme attacking the
T315I point mutation in ABL RNA to determine whether it main-
tained or enhanced the DNAzyme activity to suppress imatinib-
resistance in leukemic cells.2. Materials and methods
2.1. Oligonucleotides and reagents
The T315I and T315IL DNAzymes and DNA templates for sub-
strate RNAs (wild-type and mutant ABL RNAs) were chemically
synthesized (Cosmo Gentech, Seoul, Korea). DNA templates con-
tained the antisense sequence of the T7 promoter and sequences
for in vitro synthesis of RNAs by T7 RNA polymerase [22]. in vitro
RNA synthesis was performed as described previously [23]. OligoP-
NAs were purchased from Panagene Inc. (Daejeon, Korea). Imatinib
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(Basel, Switzerland). Imatinib stock solution (10 mg/mL) was pre-
pared by dissolving the compound in dimethylsulfoxide
(DMSO):H2O (1:1, v/v) and stored at 20 C.
2.2. In vitro RNA cleavage
RNA cleavage was performed in reaction buffer (10 mM MgCl2
and 20 mM Tris–HCl, pH 7.5) at 37 C. The reaction was initiated
by adding DNAzyme (1 lM ﬁnal concentration) to a 20-lL reaction
mixture containing substrate RNA (500 nM). The reaction mixture
was incubated for 3 h, and 1 lL of DNaseI (5 U/lL, TaKaRa, Japan)
was added to degrade the DNAzyme. After incubation for 30 min
at 37 C, the reaction was quenched by adding an equal volume
of gel-loading dye containing 25 mM Na2EDTA and 8 M urea. The
cleavage products were resolved by 8 M urea-denaturing 10%
(w/v) PAGE and RNA bands were visualized with ethidium
bromide.
2.3. Cell culture and oligonucleotide transfection
Mouse pro-B lymphoid cell lines BaF3/BCR–ABL and BaF3/BCR–
ABLT315I stably transduced with wild-type ABL and imatinib-resis-
tant mutant ABLT315I (T315I SNP), respectively, were cultured in
RPMI 1640 media containing 10% fetal bovine serum, 100 U/mL
penicillin, and 100 lg/mL streptomycin at 37 C under 5% CO2.
Chemically synthesized DNAzyme and the facilitator oligoPNA
were transfected into the cells by electroporation using the Neon
Transfection System (Invitrogen). DNAzyme was used at 4 lg in
the presence or absence of equimolar amounts of oligoPNAs per
5  105 cells and electroporated at 1,100 V with a double pulse
(30-ms pulse width). After electroporation, cells were resuspended
in RPMI medium and incubated at 37 C for 48 h.
2.4. Western blotting
Cells were lysed in RIPA buffer (50 mM Tris–HCl, pH 8.0,
150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1.0% NP40, 1 mM
PMSF) for 1 h on ice. A total of 30 lg of protein was separated by
gradient SDS–PAGE (4–12% polyacrylamide). Proteins were trans-
ferred to a nitrocellulose membrane (Whatman), and the mem-
brane was immunoblotted with anti-c-ABL monoclonal (1:500;
Santa Cruz Biotechnology, Santa Cruz, CA) and anti-b-actin anti-
bodies (1:1,500; Santa Cruz Biotechnology). The membrane was
incubated with horseradish peroxidase-conjugated anti-goat
immunoglobulin, and signals were detected with an enhanced
chemiluminescence (ECL) system (Intron Biotechnology, Seoul,
Korea).
2.5. Drug administration and cell viability
Cells grown in 24-well plates to a density of 5.0  104 cells/well
were mixed with the imatinib stock solution at increasing concen-
trations in the culture media as described above, and incubated at
37 C under 5% CO2 for 24 h. In the other case, 4 h after transfection
of DNAzyme (4 lg) in the presence or absence of equimolar
amounts of oligoPNA into cells (1.0  105 cells/well), the imatinib
solution (10 mg/mL) was added to the culture media to a ﬁnal con-
centration of 5.0 lM. The imatinib-treated cells were incubated at
37 C for 24 h. To assess cell proliferation, 50 lL of 3-(4,5)-2,5-
diphenyltetrazolium bromide (MTT; purchased from Sigma) in
PBS (2 mg/mL) was added to each well and incubated for 4 h. After
the medium was discarded, the violet formazan crystals in each
well were dissolved in 500 lL of DMSO and absorbance was mea-
sured at 570 nm in a VICTOR X3 Multilabel Plate Reader (PerkinEl-
mer). Cell viability was assayed in triplicate, and the mean value ispresented with the standard error (SE) for each sample. Differences
between samples were analyzed by 2-tailed unpaired t-tests using
SigmaPlot software (SPSS Inc, Chicago, IL, USA).
3. Results and discussion
3.1. Design of facilitator PNAs complementary to ABL RNA at the
termini of the DNAzyme
A 10–23 DNAzyme possessing a catalytic motif of 15 nts was
constructed to bind and cleave the T315I point mutation in the
ABL exon (Fig. 1A). As illustrated in Fig. 1C, two 12mer PNAs were
constructed to complement the substrate adjacent to the 5’- and
3’-end of the DNAzyme. In addition, T315I DNAzyme was engi-
neered to have a longer binding arm (T315IL DNAzyme) that can
be complementarily hybridized to the PNAs. The longer binding
arm of DNAzyme is intended to introduce oligoPNAs into cells by
annealing to the DNAzyme for efﬁcient delivery, because a major
limitation of PNA is its inefﬁcient intracellular delivery due to its
uncharged backbone [24].
T315I DNAzyme was designed to bind and cleave only the base
in the substrate RNA cleavage site (boxed sequence in Fig. 1A). The
RNA cleavage reaction was carried out with 45mer RNA substrates
with or without T315I SNP base (U). Cleavage products were visu-
alized by ethidium bromide staining as shown in Fig. 2A. The T315I
DNAzyme speciﬁcally cleaved the ABLT315I RNA substrate with a
perfectly matched base (A:U) between the DNAzyme and RNA sub-
strate, which is consistent with the previous report [7]. In contrast,
no RNA-cleavage activity toward the wild-type ABL RNA substrate
was observed.
3.2. Enhancement of T315I DNAzyme activity in cells with facilitator
PNA
The activity of DNAzyme against the target RNA sequence was
examined by monitoring expression of ABL proteins in cells. Each
DNAzyme targeting the T315I mutant ABL mRNA was transfected
into cells expressing the T315I mutant BCR–ABL. T315I DNAzyme
alone signiﬁcantly reduced expression of the mutant ABL tran-
script, whereas the T315IL DNAzyme containing the longer sub-
strate binding arm sequence (23 and 24 nts at the 30- and 50-end,
respectively) did not suppress expression of ABL mRNA (Fig. 2B).
The long binding arms in the T315IL DNAzyme are likely to have
more difﬁculty than the short binding arms in the T315I DNAzyme
in attacking potentially structured ABL mRNA in cells. As a control,
a DNAzyme with irrelevant sequence that does not match T315I
target gene (scrambled DNAzyme, ‘‘mock’’ in Fig. 2B) was also
tested. The DNAzyme with scrambled sequence did not show a sig-
niﬁcant effect on target RNA expression in cells. The other control
DNAzyme (T315I-M Dz), which abrogated RNA cleavage activity by
changing a nucleotide in the catalytic motif but retaining the same
binding arm sequences as of T315I Dz [25], was tested for ABL gene
expression in cells (Supplementary data). Similar to the scrambled
DNAzyme, the mutant DNAzyme was observed not to inhibit
expression of ABL gene (Fig. S2) as well as leukemic cell prolifera-
tion (Fig. S3), indicating that the T315I DNAzyme mainly exerts its
effect by catalytic activity of DNAzyme not by an antisense
mechanism.
To examine whether the facilitator PNA can enhance DNAzyme
activity in cells, each DNAzyme targeting the T315I mutant base
was co-transfected with PNA1 and/or PNA2. PNA2 was very effec-
tive in enhancing T315I DNAzyme activity by showing strong sup-
pression of mutant ABL expression (Fig. 2B). However, PNA1 did
not enhance T315I DNAzyme activity. Interestingly, these results
were reversed for the T315IL DNAzyme, which did not have its
own activity. After 48 h incubation of the cells treated with
AB
Fig. 2. RNA-cleavage with DNAzyme and the effect of PNAs on suppression of target gene expression. (A) T315I DNAzyme (10 lM) and substrate RNA (500 nM) were mixed
and incubated at room temperature for 3 h and separated by 10% denaturing PAGE. The T315I DNAzyme cleaves the mutant ABLT315I RNA into 2 fragments (22 mer and 23
mer), but was incapable of cleaving wild-type RNA (ABL RNA). (B) Immunoblot analysis of ABL protein from BaF3/BCR–ABLT315I cells transfected with DNAzyme (4 lg for
T315I DNAzyme or T315IL DNAzyme per 5  105 cells) and oligoPNA (equimolar amounts) with 48-h incubation. b-actin was used as a loading control. ‘‘Mock’’ represents
transfection with an oligoDNA (32mer) containing randomized sequences as a negative control.
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DNAzyme function in the cell, whereas PNA2 binding to the termi-
nus of the 50-end of DNAzyme did not yield a comparable enhance-
ment in activity. However, when the cells were incubated for a
short time period (24 h) after transfected with each PNA, both
PNAs exhibited a comparable enhancement of T315IL DNAzyme
activity (Fig. S1). These results suggest that PNA1 exhibits facilita-
tor activity at a time scale longer than 24 h after delivered into the
cells through annealing to the DNAzyme (i.e. T315IL DNAzyme).
When the two PNAs were co-transfected with each DNAzyme,
we observed that DNAzyme activity was mainly dictated by
PNA2 not PNA1, producing ABL suppression similar to that of the
facilitator PNA2. Hereafter, PNA2 was chosen as facilitator PNA to
enhance DNAzyme activity in cells, which was assessed by cell via-
bility within 24 h after treatment of facilitator PNA.
3.3. Sensitization of imatinib-resistant leukemic cells to imatinib
treatment with T315IL DNAzyme combined with facilitator PNA
The experiment was intended to reveal whether facilitator PNA
can enhance the DNAzyme activity that targets the imatinib-resis-
tant T315I point mutation, reversing drug resistance. Although
PNA2 signiﬁcantly enhances DNAzyme suppression of ABL expres-
sion in cells, we needed to conﬁrm that DNAzyme with the facili-
tator PNA produced biological sensitization of imatinib-resistant
leukemic cells. First, we tested the viability of cells treated with
increasing concentrations of imatinib mesylate using two cell lines,
imatinib-sensitive cells (BaF3/BCR–ABL) and imatinib-resistantcells (BaF3/BCR–ABLT315I). Half of the leukemic cells without
T315I SNP were dead at 3 lM of imatinib treatment for 24 h, while
the T315I mutant leukemic cells were survived at 10 lM of imati-
nib treatment (Fig. 3A).
We next determined how cell proliferation was affected by
RNA-cleaving DNAzymes with the facilitator PNA2 in the imati-
nib-resistant leukemic cells (BaF3/BCR–ABLT315I). Cells were trea-
ted with DNAzyme (T315I Dz or T315IL Dz) alone or DNAzymes
combined with PNA2 for 24 h. The T315I Dz treatment signiﬁcantly
reduced a viability of the cells, whereas the T315IL Dz treatment
showed no effect on the cell viability. Because the length of
T315I Dz (36mer) is shorter than that of T315IL Dz (62mer),
T315I Dz may have better maneuverability to ﬁnd the target RNA
sequence (i.e., T315I mutant base). When combined with DNA-
zyme treatment, imatinib further reduced cell viability in addition
to the effect caused by DNAzyme. When cells were transfected
with T315I Dz and PNA2, viability was reduced by more than
80% after imatinib treatment (asterisked bar in Fig. 3B). More
importantly, PNA2 enhanced T315IL DNAzyme activity to a level
similar to that of the T315I DNAzyme by reducing cell viability
up to 60% (Fig. 3B). This suggests that PNA2 enhances DNAzyme
activity by affecting the substrate binding step of the RNA cleavage
reaction in cells, which was previously suggested by an in vitro
study of hammerhead ribozyme [8]. Furthermore, T315IL DNA-
zyme combined with the facilitator PNA sensitized imatinib-resis-
tant leukemic cells to imatinib treatment with a signiﬁcant
reduction in cell viability (asterisked bar in Fig. 3B). Thus, the facil-
itator PNA annealed to the end of T315IL DNAzyme appeared to be
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cells.
In conclusion, the 10–23 DNAzyme, which targets the point
mutation in ABL RNA, cleaved mutant RNA with a high speciﬁcity
and suppressed ABL gene expression in cells. Use of oligoPNA as a
facilitator to enhance DNAzyme activity against long mRNA effec-
tively increased DNAzyme activity in cells. Reversal of drug-resis-
tance was demonstrated in mutant leukemic cells transfected
with the DNAzyme and facilitator PNA. The facilitator PNA prob-
ably improves the ability of the DNAzyme to ﬁnd its potentially
structured target in the ABL RNA. To date, our use of oligoPNA
as a facilitator oligonucleotide is the ﬁrst attempt to enhance
DNAzyme binding and cleaving of a disease-causing mutation in
cells. Our system should enable the facilitator PNA approach to
be generally useful to any antisense oligonucleotide for targeting
potentially interesting sites that are often masked in full-length
messages by higher-order structures in vivo.
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